Praxis Precision price target raised to $163 from $143 at Oppenheimer

Oppenheimer analyst Francois Brisebois raised the firm’s price target on Praxis Precision (PRAX) to $163 from $143 and keeps an Outperform rating on the shares. The firm recently spent time with management and comes away more positive. Looking forward to updates on the upcoming quarterly call, Oppenheimer has decided to add Praxis’s U.S. Relutrigine program for Developmental Epileptic Encephalopathy to its valuation.